Spontaneous changes in brain striatal dopamine synthesis and storage dynamics ex vivo reveal end-product feedback-inhibition of tyrosine hydroxylase

[1]  A. Ewing,et al.  Simultaneous detection of vesicular content and exocytotic release with two electrodes in and at a single cell† , 2021, Chemical science.

[2]  A. Bentivoglio,et al.  Tetrabenazine , 2009, Expert opinion on pharmacotherapy.

[3]  J. Haavik,et al.  Serine 19 phosphorylation and 14‐3‐3 binding regulate phosphorylation and dephosphorylation of tyrosine hydroxylase on serine 31 and serine 40 , 2020, Journal of neurochemistry.

[4]  P. Dickson,et al.  Tyrosine hydroxylase phosphorylation in vivo , 2019, Journal of neurochemistry.

[5]  A. Ballabio,et al.  Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis , 2019, Nature Communications.

[6]  R. Kalb,et al.  Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration , 2017, Nature Neuroscience.

[7]  J. Jankovic.  Dopamine depleters in the treatment of hyperkinetic movement disorders , 2016, Expert opinion on pharmacotherapy.

[8]  J. Sabrià,et al.  Agonist and Antagonist Effects of Aripiprazole on D2-Like Receptors Controlling Rat Brain Dopamine Synthesis Depend on the Dopaminergic Tone , 2015, The international journal of neuropsychopharmacology.

[9]  C. Cavada,et al.  Is Parkinson's Disease a Vesicular Dopamine Storage Disorder? Evidence from a Study in Isolated Synaptic Vesicles of Human and Nonhuman Primate Striatum , 2014, The Journal of Neuroscience.

[10]  K. Vrana,et al.  Complex molecular regulation of tyrosine hydroxylase , 2014, Journal of Neural Transmission.

[11]  C. Ballini,et al.  Neuroprotective Effects of the MAO‐B Inhibitor, PF9601N, in an In Vivo Model of Excitotoxicity , 2014, CNS neuroscience & therapeutics.

[12]  A. Hinck,et al.  The solution structure of the regulatory domain of tyrosine hydroxylase. , 2014, Journal of molecular biology.

[13]  G. Briggs,et al.  Catalytic domain surface residues mediating catecholamine inhibition in tyrosine hydroxylase. , 2014, Journal of biochemistry.

[14]  G. Briggs,et al.  Tyrosine hydroxylase: regulation by feedback inhibition and phosphorylation. , 2013, Advances in pharmacology.

[15]  H. Nagasaki,et al.  Intracellular stability of tyrosine hydroxylase: phosphorylation and proteasomal digestion of the enzyme. , 2013, Advances in pharmacology.

[16]  D. Goldstein,et al.  Vesicular uptake blockade generates the toxic dopamine metabolite 3,4‐dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease , 2012, Journal of neurochemistry.

[17]  L. Scott.  Tetrabenazine: for chorea associated with Huntington's disease. , 2011, CNS drugs.

[18]  K. Wimalasena.  Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry , 2011, Medicinal research reviews.

[19]  S. Daubner,et al.  Tyrosine hydroxylase and regulation of dopamine synthesis. , 2011, Archives of biochemistry and biophysics.

[20]  G. Briggs,et al.  Mutational analysis of catecholamine binding in tyrosine hydroxylase. , 2011, Biochemistry.

[21]  H. Parvez,et al.  Accumulation of phosphorylated tyrosine hydroxylase into insoluble protein aggregates by inhibition of an ubiquitin–proteasome system in PC12D cells , 2009, Journal of Neural Transmission.

[22]  H. Nijhout,et al.  Theoretical Biology and Medical Modelling Open Access Homeostatic Mechanisms in Dopamine Synthesis and Release: a Mathematical Model , 2022 .

[23]  M. Carrascal,et al.  Discovery of lipoprotein lipase pI isoforms and contributions to their characterization. , 2009, Journal of proteomics.

[24]  P. Dickson,et al.  The Low Affinity Dopamine Binding Site on Tyrosine Hydroxylase: The Role of the N-Terminus and In Situ Regulation of Enzyme Activity , 2009, Neurochemical Research.

[25]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[26]  N. Hayashi,et al.  Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines , 2009, Journal of Neural Transmission.

[27]  E O Voit,et al.  A Mathematical Model of Presynaptic Dopamine Homeostasis: Implications for Schizophrenia , 2008, Pharmacopsychiatry.

[28]  P. Dickson,et al.  Tyrosine hydroxylase activity is regulated by two distinct dopamine‐binding sites , 2008, Journal of neurochemistry.

[29]  Eberhard O. Voit,et al.  Computational Systems Analysis of Dopamine Metabolism , 2008, PloS one.

[30]  J. Haavik,et al.  Endogenous tetrahydroisoquinolines associated with Parkinson’s disease mimic the feedback inhibition of tyrosine hydroxylase by catecholamines , 2008, The FEBS journal.

[31]  L. Wallace.  A small dopamine permeability of storage vesicle membranes and end product inhibition of tyrosine hydroxylase are sufficient to explain changes occurring in dopamine synthesis and storage after inhibition of neuron firing , 2007, Synapse.

[32]  M. F. Salvatore,et al.  Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia. , 2007, The Journal of neuropsychiatry and clinical neurosciences.

[33]  D. Sulzer,et al.  α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration , 2006, The Journal of Neuroscience.

[34]  A. Carlsson,et al.  Potentiation of phenothiazines byα-methyltyrosine in treatment of chronic schizophrenia , 2005, Journal of Neural Transmission.

[35]  M. Graham,et al.  Tyrosine hydroxylase phosphorylation: regulation and consequences , 2004, Journal of neurochemistry.

[36]  S. Daubner,et al.  Effects of phosphorylation by protein kinase A on binding of catecholamines to the human tyrosine hydroxylase isoforms , 2004 .

[37]  S. Daubner,et al.  Effects of phosphorylation by protein kinase A on binding of catecholamines to the human tyrosine hydroxylase isoforms , 2004, Journal of neurochemistry.

[38]  D. Goldstein,et al.  Leaky Catecholamine Stores: Undue Waste or a Stress Response Coping Mechanism? , 2004, Annals of the New York Academy of Sciences.

[39]  N. Andén,et al.  Effects of drugs influencing monoamine mechanisms on the increase in brain dopamine produced by axotomy or treatment with gammahydroxybutyric acid , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[40]  P. Shapiro,et al.  Inhibition of aldose reductase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases , 2002, Anti-cancer drugs.

[41]  T. Hökfelt,et al.  Activation of extracellular signal‐regulated kinases 1 and 2 by depolarization stimulates tyrosine hydroxylase phosphorylation and dopamine synthesis in rat brain , 2002, The European journal of neuroscience.

[42]  S. Daubner,et al.  Effects of substitution at serine 40 of tyrosine hydroxylase on catecholamine binding. , 2001, Biochemistry.

[43]  T. Hökfelt,et al.  Regulation of Tyrosine Hydroxylase Activity and Phosphorylation at Ser19 and Ser40 via Activation of Glutamate NMDA Receptors in Rat Striatum , 2000, Journal of neurochemistry.

[44]  J. Gómez,et al.  Quantitative radioisotopic determination of histidine decarboxylase using high-performance liquid chromatography. , 2000, Analytical biochemistry.

[45]  A. Ramsey,et al.  Effects of phosphorylation of serine 40 of tyrosine hydroxylase on binding of catecholamines: evidence for a novel regulatory mechanism. , 1998, Biochemistry.

[46]  J. Haycock,et al.  Regulation of l‐DOPA Biosynthesis by Site‐Specific Phosphorylation of Tyrosine Hydroxylase in AtT‐20 Cells Expressing Wild‐Type and Serine 40‐Substituted Enzyme , 1996, Journal of neurochemistry.

[47]  J. Ludders.  Advantages and guidelines for using isoflurane. , 1992, The Veterinary clinics of North America. Small animal practice.

[48]  J. Haycock,et al.  Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple-site phosphorylation in vivo and in synaptosomes. , 1991, The Journal of biological chemistry.

[49]  J. B. Justice,et al.  Modeling the dopaminergic nerve terminal , 1988, Journal of Neuroscience Methods.

[50]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[51]  T. Nagatsu.  REGULATION OF TYROSINE HYDROXYLASE , 1979 .

[52]  W. Lovenberg,et al.  Regulation of tyrosine hydroxylase activity. , 1977, Advances in biochemical psychopharmacology.

[53]  R. Roth,et al.  Dopaminergic neurons: similar biochemical and histochemical effects of gamma-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway. , 1973, The Journal of pharmacology and experimental therapeutics.

[54]  R. Roth,et al.  Gamma-hydroxybutyrate-induced increase in brain dopamine: localization by fluorescence microscopy. , 1970, The Journal of pharmacology and experimental therapeutics.

[55]  T Nagatsu,et al.  [Tyrosine hydroxylase]. , 1969, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[56]  A. Sjoerdsma,et al.  End-product inhibition of tyrosine hydroxylase as a possible mechanism for regulation of norepinephrine synthesis. , 1967, Molecular pharmacology.